| Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone. | |
| | |
MedLine Citation:
|
PMID: 9602955 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effect of famotidine, an H2 receptor blocker, on the oral absorption and pharmacokinetics of the novel agent vesnarinone was investigated after oral administration of 60 mg vesnarinone with and without pretreatment with intravenous famotidine. The single-blind, randomized, two-way crossover study was conducted in 12 volunteers, with a washout period of 7 days between the two treatments. A pH monitor was used to ensure that gastric pH of the subjects was < or = 3 in the absence of and > or = 5 in the presence of famotidine. A significant decrease in maximum concentration (Cmax) and increase in time to Cmax (tmax) was observed for vesnarinone during treatment with famotidine, whereas area under the concentration-time curve (AUC) was similar for both treatments. The physicochemical properties of the drug support the above observations. Therefore, therapies that increase gastric pH will affect the rate but not the extent of absorption of vesnarinone or the safety or efficacy profile of vesnarinone. |
| | |
Authors:
|
B Koneru; D T Cowart; M Noorisa; J Kisicki; S L Bramer |
Related Documents
:
|
10736365 - Intestinal glutamate metabolism. 530905 - Fatty acid binding protein in the intestine of the chicken. 1990885 - Bacterial overgrowth and intestinal atrophy in the etiology of gut barrier failure in t... 8395805 - Experimental infection of specific-pathogen-free turkey poults with single and combined... 6752895 - Zinc, copper, and manganese in immune function and experimental oncogenesis. 2122965 - Use of a liquid diet as the sole source of nutrition in six dysphagic horses and as a d... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 38 ISSN: 0091-2700 ISO Abbreviation: J Clin Pharmacol Publication Date: 1998 May |
Date Detail:
|
Created Date: 1998-07-07 Completed Date: 1998-07-07 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 429-32 Citation Subset: IM |
Affiliation:
|
Otsuka America Pharmaceutical, Inc., Rockville, Maryland 20850, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Area Under Curve Cardiotonic Agents / administration & dosage, pharmacokinetics*, urine Cross-Over Studies Double-Blind Method Drug Interactions Famotidine / pharmacology* Female Histamine H2 Antagonists / pharmacology* Humans Hydrogen-Ion Concentration / drug effects Intestinal Absorption / drug effects* Male Metabolic Clearance Rate Quinolines / administration & dosage, pharmacokinetics*, urine |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Histamine H2 Antagonists; 0/Quinolines; 76824-35-6/Famotidine; 81840-15-5/vesnarinone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase.
Next Document: Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.